Sandhya Srinivas

8.0k total citations
18 papers, 748 citations indexed

About

Sandhya Srinivas is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Sandhya Srinivas has authored 18 papers receiving a total of 748 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 9 papers in Cancer Research and 6 papers in Molecular Biology. Recurrent topics in Sandhya Srinivas's work include Renal cell carcinoma treatment (10 papers), Cancer Genomics and Diagnostics (9 papers) and Renal and related cancers (6 papers). Sandhya Srinivas is often cited by papers focused on Renal cell carcinoma treatment (10 papers), Cancer Genomics and Diagnostics (9 papers) and Renal and related cancers (6 papers). Sandhya Srinivas collaborates with scholars based in United States, France and Denmark. Sandhya Srinivas's co-authors include Bernard Escudier, Jan Roigas, Christian Peschel, Silke Gillessen, George Fountzilas, Per Flodgren, Ulrika Harmenberg, Nicholas J. Vogelzang, Roberto A. Novoa and Heather A. Wakelee and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Sandhya Srinivas

16 papers receiving 739 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandhya Srinivas United States 9 479 396 250 199 78 18 748
Pavlos Papakotoulas Greece 16 777 1.6× 426 1.1× 144 0.6× 292 1.5× 109 1.4× 52 1.0k
Anne Flörcken Germany 17 320 0.7× 460 1.2× 357 1.4× 229 1.2× 85 1.1× 61 889
Vincenzo Emanuele Chiurì Italy 12 478 1.0× 456 1.2× 213 0.9× 189 0.9× 67 0.9× 35 703
B. Nelson United States 7 795 1.7× 278 0.7× 295 1.2× 84 0.4× 167 2.1× 12 1.0k
Antonio Santo Italy 16 357 0.7× 402 1.0× 121 0.5× 110 0.6× 83 1.1× 55 786
Shaan Dudani Canada 14 420 0.9× 536 1.4× 271 1.1× 246 1.2× 141 1.8× 48 765
Emi Noguchi Japan 12 352 0.7× 208 0.5× 115 0.5× 120 0.6× 51 0.7× 63 608
Francesca Mazzoni Italy 18 568 1.2× 470 1.2× 178 0.7× 160 0.8× 67 0.9× 63 821
Francis Parnis Australia 14 328 0.7× 457 1.2× 186 0.7× 160 0.8× 112 1.4× 60 761
A. Van Oosterom Belgium 11 268 0.6× 209 0.5× 228 0.9× 124 0.6× 62 0.8× 28 572

Countries citing papers authored by Sandhya Srinivas

Since Specialization
Citations

This map shows the geographic impact of Sandhya Srinivas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandhya Srinivas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandhya Srinivas more than expected).

Fields of papers citing papers by Sandhya Srinivas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandhya Srinivas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandhya Srinivas. The network helps show where Sandhya Srinivas may publish in the future.

Co-authorship network of co-authors of Sandhya Srinivas

This figure shows the co-authorship network connecting the top 25 collaborators of Sandhya Srinivas. A scholar is included among the top collaborators of Sandhya Srinivas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandhya Srinivas. Sandhya Srinivas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Srinivas, Sandhya, et al.. (2021). A Potential Role for Antifibrotic Use in Post-COVID-19 Pulmonary Fibrosis. A4091–A4091. 1 indexed citations
2.
Joseph, Arun, et al.. (2019). Effect of Sagittal Dentoskeletal Discrepancies on the Vermilion Height and Lip Area. SHILAP Revista de lepidopterología. 32(2). 79–86. 1 indexed citations
3.
Nobashi, Tomomi W., Lucia Baratto, Sunil Reddy, et al.. (2019). Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. Clinical Nuclear Medicine. 44(4). e272–e279. 75 indexed citations
4.
5.
Escudier, Bernard, Padmanee Sharma, David F. McDermott, et al.. (2017). CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. European Urology. 72(6). 962–971. 184 indexed citations
6.
Wells, J. Connor, Frede Donskov, Georg A. Bjarnason, et al.. (2016). First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology. 34(2_suppl). 544–544. 1 indexed citations
7.
Schaberg, Kurt B., Roberto A. Novoa, Heather A. Wakelee, et al.. (2016). Immunohistochemical analysis of lichenoid reactions in patients treated with anti‐PD‐L1 and anti‐PD‐1 therapy. Journal of Cutaneous Pathology. 43(4). 339–346. 104 indexed citations
8.
Motzer, Robert J., Padmanee Sharma, David F. McDermott, et al.. (2016). CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 34(2_suppl). 498–498. 27 indexed citations
9.
Velasco, Guillermo de, Wanling Xie, Frede Donskov, et al.. (2016). Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 34(2_suppl). 503–503.
10.
Fan, Alice C., John T. Leppert, Liwen Xu, et al.. (2013). Abstract 2283: Nano-scale proteomic profiles of response to targeted therapy in patients with RCC.. Cancer Research. 73(8_Supplement). 2283–2283. 1 indexed citations
11.
Cann, Gordon, Zulfiqar Gulzar, Samantha Cooper, et al.. (2012). mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer. PLoS ONE. 7(11). e49144–e49144. 107 indexed citations
12.
Harshman, Lauren C., Andrew McMillan, & Sandhya Srinivas. (2010). Treatment of refractory metastatic renal cell carcinoma (RCC) with bevacizumab and RAD001.. Journal of Clinical Oncology. 28(15_suppl). TPS236–TPS236. 1 indexed citations
13.
Escudier, Bernard, Jan Roigas, Silke Gillessen, et al.. (2009). Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(25). 4068–4075. 164 indexed citations
14.
Harshman, Lauren C., et al.. (2008). Bevacizumab-associated erythrocytosis in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 26(15_suppl). 16096–16096. 2 indexed citations
15.
Ross, Robert W., Ramaprasad Srinivasan, Ulka N. Vaishampayan, et al.. (2007). A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC).. Molecular Cancer Therapeutics. 6. 7 indexed citations
16.
Srinivas, Sandhya, Jan Roigas, Silke Gillessen, et al.. (2007). Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results. Journal of Clinical Oncology. 25(18_suppl). 5040–5040. 25 indexed citations
17.
Mulder, P H de, Jan Roigas, Silke Gillessen, et al.. (2006). A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 24(18_suppl). 4529–4529. 31 indexed citations
18.
Reilly, Brendan M., et al.. (1993). Intravenous heparin dosing. Journal of General Internal Medicine. 8(10). 536–542. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pavlos Papakotoulas Breakdown of academic impact, for papers by Anne Flörcken Breakdown of academic impact, for papers by Vincenzo Emanuele Chiurì Breakdown of academic impact, for papers by B. Nelson Breakdown of academic impact, for papers by Antonio Santo Breakdown of academic impact, for papers by Shaan Dudani Breakdown of academic impact, for papers by Emi Noguchi Breakdown of academic impact, for papers by Francesca Mazzoni Breakdown of academic impact, for papers by Francis Parnis Breakdown of academic impact, for papers by A. Van Oosterom
Rankless by CCL
2026